1. Pink Sheet
  2. >>Rare Diseases

EMA ‘Trying Its Best’ To Offer More Early Scientific Support For Sponsors

 
• By Eliza Slawther

The head of the European Medicines Agency’s scientific advisory office is hopeful that the organization’s PRIME initiative will be enshrined in EU legislation over the coming years, rather than just existing as an initiative from the agency.

Male and female hands holding tight together on black isolated background. Love, relations, support, together forever concept. Copy space, cutout, low key

The European Medicines Agency is aware that its US counterpart, the Food and Drug Administration, offers a “much higher variety” of early support mechanisms for sponsors, but it is aiming to support companies as much as it can, according to the head of the agency’s scientific advisory office, Iordanis Gravanis.

During an interactive EMA event, Gravanis noted that while the EMA does not have as many mechanisms in place to...

Welcome to Pink Sheet

Create an account to read this article

Already a subscriber?

More from Rare Diseases

More from Pink Sheet

EU Must Up Competitiveness To Counter US Tariffs And Pricing Woes For SMEs

 
• By Francesca Bruce

Companies in Europe cannot delay business decision making much longer to wait for more certainty on major US policy shifts on tariffs and pricing.

Global Pharma Guidance Tracker - July 2025

 
• By Vibha Sharma and Anabel Costa-Ferreira

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Research Advances And Filings Prompt EMA To Revise Alzheimer’s Trial Guideline

 
• By Neena Brizmohun

Following EU approval of the first disease-modifying treatment for Alzheimer’s disease, and with a second expected soon, the European Medicines Agency plans to update its guidance to support the design of state-of-the-art clinical trials for the disease and enhance drug development.